- IN₹9.59bn
- IN₹11.73bn
- IN₹6.50bn
Brief: Wanbury Expanded Regulatory Submission For New Active Pharmaceutical Ingredients
Brief: Wanbury Says Patalganga Site Has Completed Korea FDA Regulatory Inspection Successfully
Brief: Wanbury Ltd Launches Coriminic CPM Drops For Pediatric Use
Brief: Wanbury Receives Sertraline Form II Approval From Anvisa, Brazil
Brief: Wanbury Ltd Launches Commercial Production Of Anaesthetic API
India's Wanbury jumps after facility clears Brazil regulator's inspection
Indian pharma firm Wanbury gains on product launch plans
Brief: Wanbury To Issue NCDs Up To 2 Billion Rupees
Brief: Wanbury Ltd Completes ANVISA Audit At Tanuku Plant
Brief: Wanbury Says Tanuku Plant Completes Anvisa Inspection
Brief: Wanbury- Got Certificate Of Suitability For Launch Of Dextromethorpha From European Regulator
India's Wanbury rises after Maharashtra facility gets U.S. FDA nod
India's Wanbury rises after USFDA inspection shows zero observations
Brief: Wanbury March-Qtr Consol PAT Rises
Brief: India's Wanbury Sept-Quarter Consol PAT At 73.6 Million Rupees
Brief: Wanbury To Consider Raising Of Funds
Brief: India's Wanbury Reports Profit For June-Qtr
Brief: Wanbury To Consider Issue Of Nonconvertible Debentures On Private Placement Basis
Brief: India's Wanbury Posts Dec-Qtr Loss After Tax vs Profit a Year Ago